Title:
Protocol for a research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries. View
Indication:
Blood and Marrow Transplant
Location:
Texas Oncology-Amarillo Cancer Center
Title:
PNH (Paroxysmal Nocturnal Hemoglobiniuria) Registry View
Indication:
Miscellaneous
Location:
Texas Oncology-Amarillo Cancer Center
Title:
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View
Indication:
Hematologic
Location:
Texas Oncology-Amarillo Cancer Center
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)
Indication:
Bladder Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Bladder Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
Adj Therapy Node+orHRNode-3-Inv TNBC View
Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
STAR Open Label VT-464 Adv Breast Cancer View
Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Cape/tras +/- ONT-380 HER2+ mBC View
Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
Ph3 Abemaciclib HR+ HER2- (monarchE) View
Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
Ph IV Obsv LowRisk MF [MOST] View
Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Ph IV Obsv LowRisk MF [MOST] View
Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)
Indication:
Hematologic
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Molecular Markers - Malignant Tumors View
Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)
Indication:
Hematologic
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
informCLL™ Registry View
Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)
Indication:
Leukemia
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Cypress 2: Ph2 AM0010+Nivo NSCLC View
Description: A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1 (AM0010-202)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Brentux in older pts w/HL 1L View
Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above
Indication:
Lymphomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
MAGNIFY Rev+Ritux, R/R FL, MZL, MCL View
Description: A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCE VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA (CC-5013-NHL-008)(MAGNIFY)
Indication:
Lymphomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
Ph IV Obsv LowRisk MF [MOST] View
Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)
Indication:
Myelofibrosis
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR Ph2 Itacitinib +/- Ruxo in MF View
Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Indication:
Myelofibrosis
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
PREAMBLE - Observational in 1L & R/R MM View
Description: CA204-008: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE)
Indication:
Myelomas
Location:
Texas Oncology-Amarillo Cancer Center
Title:
Observational INSIGHT MM study View
Description: A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT MM study (NSMM-5001)
Indication:
Myelomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR Ph2 Rucaparib mCRPC (TRITON 2) View
Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052
Indication:
Prostate Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
Molecular Markers - Malignant Tumors View
Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR INCB054828 Urothelial FGF/FGFR View
Description: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB 54828-201)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 enfortumab (ASG-22CE)Urothelial View
Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001
Indication:
Urothelial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II